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Screening for Abdominal Aortic Aneurysm
US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force
IMPORTANCE An abdominal aortic aneurysm (AAA) is typically defined as aortic enlargement
with a diameter of 3.0 cm or larger. The prevalence of AAA has declined over the past 2
decades among screened men 65 years or older in various European countries. The current
prevalence of AAA in the United States is unclear because of the low uptake of screening.
Most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly
by aneurysm size, the associated risk for death with rupture is as high as 81%.
OBJECTIVE To update its 2014 recommendation, the USPSTF commissioned a review of the
evidence on the effectiveness of 1-time and repeated screening for AAA, the associated
harms of screening, and the benefits and harms of available treatments for small AAAs
(3.0-5.4 cm in diameter) identified through screening.
POPULATION This recommendation applies to asymptomatic adults 50 years or older.
However, the randomized trial evidence focuses almost entirely on men aged 65 to 75 years.
EVIDENCE ASSESSMENT Based on a review of the evidence, the USPSTF concludes with
moderate certainty that screening for AAA in men aged 65 to 75 years who have ever smoked
is of moderate net benefit. The USPSTF concludes with moderate certainty that screening for
AAA in men aged 65 to 75 years who have never smoked is of small net benefit. The USPSTF
concludes that the evidence is insufficient to determine the net benefit of screening for AAA
in women aged 65 to 75 years who have ever smoked or have a family history of AAA. The
USPSTF concludes with moderate certainty that the harms of screening for AAA in women
aged 65 to 75 years who have never smoked and have no family history of AAA outweigh the
benefits.
RECOMMENDATIONS The USPSTF recommends 1-time screening for AAA with
ultrasonography in men aged 65 to 75 years who have ever smoked. (B recommendation)
The USPSTF recommends that clinicians selectively offer screening for AAA with
ultrasonography in men aged 65 to 75 years who have never smoked rather than routinely
screening all men in this group. (C recommendation) The USPSTF recommends against
routine screening for AAA with ultrasonography in women who have never smoked and have
no family history of AAA. (D recommendation) The USPSTF concludes that the current
evidence is insufficient to assess the balance of benefits and harms of screening for AAA with
ultrasonography in women aged 65 to 75 years who have ever smoked or have a family
history of AAA. (I statement)
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Summary of Recommendations
Importance
An AAA is typically defined as aortic enlargement with a diameter
of 3.0 cm or larger. The prevalence of AAA has declined over the past
2 decades among screened men 65 years or older in various coun-
tries such as the United Kingdom, New Zealand, Sweden, and
Denmark.1-10 Population-based studies in men older than 60 years
have found an AAA prevalence ranging from 1.2% to 3.3%.1-10 The
reduction in prevalence is attributed to the decrease in smoking
prevalence over time. Previous prevalence rates of AAA reported in
population-based screening studies ranged from 1.6% to 7.2% of the
general population 60 to 65 years or older.1 The current preva-
lence of AAA in the United States is unclear because of the low up-
take of screening.1 Most AAAs are asymptomatic until they rup-
ture. Although the risk for rupture varies greatly by aneurysm size,
the associated risk for death with rupture is as high as 81%.1,11
USPSTF Assessment of Magnitude of Net Benefit
The USPSTF concludes with moderate certainty that screening
for AAA in men aged 65 to 75 years who have ever smoked
is of moderate net benefit (Figure and Table; see the eFigure
in the Supplement for explanation of USPSTF grades and levels
of evidence).
The USPSTF concludes with moderate certainty that screen-
ing for AAA in men aged 65 to 75 years who have never smoked is
of small net benefit (Figure and Table).
The USPSTF concludes that the evidence is insufficient to de-
termine the net benefit of screening for AAA in women aged 65 to
75 years who have ever smoked or have a family history of AAA
(Figure and Table).
The USPSTF concludes with moderate certainty that the harms
of screening for AAA in women aged 65 to 75 years who have never
smoked and have no family history of AAA outweigh the benefits
(Figure and Table).
For more details on the methods the USPSTF uses to deter-
mine the net benefit, see the USPSTF Procedure Manual.12
Practice Considerations
Patient Population Under Consideration
Based on the scope of the evidence review, this recommendation
applies to asymptomatic adults 50 years or older. However, the
randomized trial evidence focuses almost entirely on men aged 65
to 75 years. In this Recommendation Statement, the recommenda-
tions are stratified by “men” and “women,” although the net benefit
estimates are driven by biologic sex (ie, male/female) rather than
gender identity. Persons should consider their sex at birth to deter-
mine which recommendation best applies to them.
Assessment of Risk
Important risk factors for AAA include older age, male sex,
smoking, and having a first-degree relative with an AAA.13-16
Other risk factors include a history of other vascular aneurysms,
coronary artery disease, cerebrovascular disease, atherosclerosis,
hypercholesterolemia, and hypertension.17-19 Factors associated
with a reduced risk include African American race, Hispanic eth-
nicity, Asian ethnicity, and diabetes.13,20-24 Risk factors for AAA
rupture include older age, female sex, smoking, and elevated
blood pressure.1 Clinicians should consider the presence of
comorbid conditions and not offering screening if patients are
unable to undergo surgical intervention or have a reduced
life expectancy.
Smoking Status
Epidemiologic literature commonly defines an “ever smoker” as
someone who has smoked 100 or more cigarettes. Indirect evi-
dence shows that smoking is the strongest predictor of AAA preva-
lence, growth, and rupture rates.1 There is a dose-response relation-
ship, as greater smoking exposure is associated with an increased
risk for AAA.1
The USPSTF concludes that the current evidence is insufficient to assess the
balance of benefits and harms of screening for AAA with ultrasonography in
women aged 65 to 75 years who have ever smoked or have a family history
of AAA.
I statement
The USPSTF recommends 1-time screening for abdominal aortic aneurysm
(AAA) with ultrasonography in men aged 65 to 75 years who have ever smoked.
The USPSTF recommends that clinicians selectively offer screening for AAA with
ultrasonography in men aged 65 to 75 years who have never smoked rather than
routinely screening all men in this group. Evidence indicates that the net benefit
of screening all men in this group is small. In determining whether this service
is appropriate in individual cases, patients and clinicians should consider the
balance of benefits and harms on the basis of evidence relevant to the patient’s
medical history, family history, other risk factors, and personal values.
B recommendation
C recommendation
The USPSTF recommends against routine screening for AAA with
ultrasonography in women who have never smoked and have no family
history of AAA.
D recommendation
See the Figure for a more detailed
summary of the recommendation for
clinicians. See the “Practice
Considerations” section for more
information on each of these
populations. USPSTF indicates US
Preventive Services Task Force.
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Family History
Family history of AAA in a first-degree relative doubles the risk of
developing AAA.25 The risk of developing an AAA is stronger with a
female first-degree relative (odds ratio [OR], 4.32) than with a male
first-degree relative (OR, 1.61).1,25 However, evidence is lacking on
whether persons with family history experience a different natural
history or surgical outcomes than those without such a history.1
Screening Tests
The primary method of screening for AAA is conventional abdomi-
nal duplex ultrasonography.26 Screening with ultrasonography is non-
invasive, is simple to perform, has high sensitivity (94%-100%) and
specificity (98%-100%) for detecting AAA,1,27-31 and does not ex-
pose patients to radiation. Computed tomography is an accurate tool
for identifying AAA; however, it is not recommended as a screen-
ing method because of the potential for harms from radiation
exposure.1 Physical examination has been used in practice but has
low sensitivity (39%-68%) and specificity (75%) and is not recom-
mended for screening.32
Screening Intervals
Evidence is adequate to support 1-time screening for men who have
ever smoked. All of the population-based randomized clinical trials
(RCTs) of AAA screening used a 1-time screening approach; 7 fair-
to good-quality cohort studies and 1 fair-quality case-control study
(n = 6785) show that AAA-associated mortality over 5 to 12 years is
rare (<3%) in men with initially normal results on ultrasonography
(defined as an AAA <3 cm in diameter).1
Treatment
Treatment of AAA depends on aneurysm size, the risk of rupture,
and the risk of operative mortality. Larger size is associated with an
increased risk of rupture. The annual risk for rupture is nearly 0%
for persons with AAAs between 3.0 and 3.9 cm in diameter, 1% for
those with AAAs between 4.0 and 4.9 cm in diameter, and 11% for
those with AAAs between 5.0 and 5.9 cm in diameter.1 Surgical re-
pair is standard practice for men with an AAA of 5.5 cm or larger in
diameter or an AAA larger than 4.0 cm in diameter that has rapidly
increased in size (defined as an increase of 1.0 cm in diameter over
a 1-year period). Endovascular aneurysm repair (EVAR) has be-
come the most common approach for elective AAA repair. Open re-
pair is a time-tested, effective treatment for AAA. In the United
States, 80% of intact AAA repairs and 52% of ruptured AAA re-
pairs are performed using EVAR.1
The majority of screen-detected AAAs (90%) are between 3.0
and 5.5 cm in diameter and thus below the usual threshold for
Figure. Clinician Summary: Screening for Abdominal Aortic Aneurysm
What does the USPSTF
recommend?
For men aged 65 to 75 years who have ever smoked: Grade B
To whom does this
recommendation apply?
What’s new?
How to implement this
recommendation?
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize
decision-making to the specific patient or situation.
Asymptomatic adults
How often? One-time screening
What are other
relevant USPSTF
recommendations?
The USPSTF has made recommendations on screening for carotid artery stenosis and screening for peripheral arterial disease.
These recommendations are available at https://www.uspreventiveservicestaskforce.org.
This recommendation is consistent with the 2014 USPSTF recommendation. Family history (first-degree relative) of AAA has
been added as a risk factor for screening decisions in women.  
For those who screen positive, treatment of AAA will depend on aneurysm size, the risk of rupture, and the risk
of operative mortality.
Perform 1-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men who have a history of smoking.
For men aged 65 to 75 years who have never smoked: Grade C
Selectively offer screening to men who do not have a history of smoking, rather than routinely screening all men in this group. 
For women who have never smoked and have no family history of AAA: Grade D
Do not screen women who have never smoked and do not have a family history of AAA.
December 2019
For women aged 65 to 75 years who have ever smoked or have a family history of AAA: I statement
Evidence is insufficient to assess the balance of benefits and harms of screening for AAA with ultrasonography in women
aged 65 to 75 years who have ever smoked or have a family history of AAA.
Assess risk. Risk factors for AAA include older age, male sex, smoking, and having a first-degree relative with an AAA.
The recommendation varies based on a patient’s sex, age, and smoking history. “Ever smoker” is commonly defined as
smoking 100 or more cigarettes. 
1.
Screen. Abdominal duplex ultrasonography is the standard approach for AAA screening.
a. Screen men aged 65 to 75 years who have ever smoked.
b. Selectively offer screening to men aged 65 to 75 years who have never smoked. Evidence shows that the overall benefit
for screening all men in this group is small. To determine whether this service is appropriate, patients and clinicians
should consider the patient’s medical history, family history, other risk factors, and personal values.
2.
AAA indicates abdominal aortic aneurysm; USPSTF, US Preventive Services Task Force.
USPSTF Recommendation: Screening for Abdominal Aortic Aneurysm US Preventive Services Task Force Clinical Review & Education
jama.com (Reprinted) JAMA December 10, 2019 Volume 322, Number 22 2213
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Massachusetts User  on 01/30/2020
surgery. The current standard of care for patients with stable smaller
aneurysms is to maintain ultrasound surveillance at regular inter-
vals because the risk of rupture is small. Recommended surveil-
lance intervals for monitoring the growth of small AAAs vary across
guideline groups, and adherence with surveillance guidelines has
been reported to be as low as 65%.1 Repairing smaller aneurysms
with a lower risk of rupture increases the harms and reduces the ben-
efits of screening.
Suggestions for Practice Regarding the I Statement
Potential Preventable Burden
The estimated prevalence of AAA in women is reportedly less than
that in men.1 The Chichester trial reported a prevalence in women
that was one-sixth of the prevalence in men (1.3% vs 7.6%), and most
AAA-related deaths occurred in women 80 years or older (70% vs
<50% in men).33 In women, small AAAs have an increased risk of rup-
ture, and rupture at an older age than in men.1 Studies estimate that
one-fourth to one-third of women have an AAA with a diameter be-
low the current 5.5-cm threshold at the time of rupture.1
Potential Harms
Operative mortality associated with AAA is higher in women than
in men. Women had higher 30-day mortality rates (2.31%) than men
(1.37%) after EVAR procedures (OR, 1.67 [95% CI, 1.38-2.04]) and
open repair (5.37% vs 2.82%; OR, 1.76 [95% CI, 1.35-2.30]).1,34
Women also experience higher rates of other harms, such as major
surgical complications and hospital readmission, after elective open
repair or EVAR compared with men.1
Current Practice
Evidence is insufficient to accurately characterize current practice
patterns related to screening for AAA in women.
The standard of care for elective repair is that patients with an
AAA of 5.5 cm or larger in diameter should be referred for surgical
intervention with either open repair or EVAR.1 This recommenda-
tion is based on RCTs conducted in men. The AAA size needed for
surgical intervention in women may differ. As a result, guidelines from
the Society for Vascular Surgery recommend repairing AAAs be-
tween 5.0 and 5.4 cm in diameter in women.26 However, concerns
about poorer surgical outcomes in women, who have more com-
plex anatomy and smaller blood vessels, have led some to caution
against lowering the threshold for surgical intervention in women.1
Update of Previous USPSTF Recommendation
This recommendation incorporates new evidence and replaces the
2014 USPSTF recommendation.35 It is consistent with the 2014
USPSTF recommendation, which was a B recommendation for 1-time
screening for AAA with ultrasonography in asymptomatic men aged
65 to 75 years who have ever smoked, a C recommendation for se-
lective screening in men aged 65 to 75 years who have never smoked,
a D recommendation against routine screening in asymptomatic
women who have never smoked, and an I statement for women aged
65 to 75 years who have ever smoked.
Supporting Evidence
Scope of Review
The USPSTF commissioned a systematic evidence review to up-
date its 2014 recommendation on screening for AAA. The USPSTF
examined evidence regarding the effectiveness of 1-time and re-
peated screening for AAA, the associated harms of screening, and
Table. Summary of USPSTF Rationalea
Rationale
Men Women
Ever Smoked Never Smoked Ever Smoked or Family History
Never Smoked and No Family
History
Detection There is adequate evidence
that ultrasonography is a safe
and accurate screening test
for AAA
There is adequate evidence
that ultrasonography is a safe
and accurate screening test
for AAA
There is adequate evidence
that ultrasonography is a safe
and accurate screening test
for AAA
There is adequate evidence
that ultrasonography is a safe
and accurate screening test
for AAA
Benefits of early detection and
treatment (based on direct or
indirect evidence)
There is adequate evidence
that 1-time screening for AAA
with ultrasonography results
in a moderate benefit in men
aged 65 to 75 y who have ever
smoked
There is adequate evidence
that 1-time screening for AAA
with ultrasonography results
in a small benefit in men aged
65 to 75 y who have never
smoked
There is inadequate evidence
to conclude whether 1-time
screening for AAA with
ultrasonography is beneficial
in women aged 65 to 75 y who
have ever smoked or have a
family history of AAA
There is adequate evidence
that 1-time screening for AAA
with ultrasonography results
in no benefit in women who
have never smoked and have
no family history of AAA
Harms of early detection and
treatment
There is adequate evidence
that the harms associated with
1-time screening for AAA with
ultrasonography are small to
moderate
There is adequate evidence
that the harms associated with
1-time screening for AAA with
ultrasonography are small to
moderate
There is adequate evidence
that the harms associated with
1-time screening for AAA with
ultrasonography are small to
moderate
There is adequate evidence
that the harms associated with
1-time screening for AAA with
ultrasonography are small to
moderate
USPSTF assessment There is moderate certainty
that screening for AAA with
ultrasonography in men aged
65 to 75 y who have ever
smoked has a moderate net
benefit
There is moderate certainty
that screening for AAA with
ultrasonography in men aged
65 to 75 y who have never
smoked has a small net
benefit
The benefits and harms of
screening for AAA with
ultrasonography in women
aged 65 to 75 y who have ever
smoked or have a family
history of AAA are uncertain,
and the balance of benefits
and harms cannot be
determined
There is moderate certainty
that the harms of screening
for AAA with ultrasonography
in women who have never
smoked and have no family
history of AAA outweigh the
benefits
Abbreviations: AAA, abdominal aortic aneurysm; USPSTF, US Preventive
Services Task Force.
a See the eFigure in the Supplement for explanation of USPSTF grades and
levels of evidence.
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the benefits and harms of available treatments for small AAAs
(3.0-5.4 cm in diameter) identified through screening.
Accuracy of Screening Tests and Risk Assessment
Ultrasonography is the primary method used to screen for AAA in
primary care because of its high sensitivity (94%-100%) and speci-
ficity (98%-100%).1 It is also noninvasive, is simple to perform, and
does not expose patients to radiation.
Benefits of Early Detection and Treatment
Screening
Four large, population-based RCTs (n = 134 271) that predomi-
nantly enrolled men 65 years or older examined the effectiveness
of 1-time screening for AAA: the good-quality Multicenter Aneu-
rysm Screening Study (MASS) (n = 67 800)36; the good-quality
Viborg County, Denmark, screening trial (n = 12 639)13; the fair-
quality Chichester, United Kingdom, screening trial (n = 15 382)37;
and the fair-quality Western Australia screening trial (n = 38 480).38
Reported mean (or median) ages ranged from 67.7 to 72.6 years; the
oldest participants were aged 83 years.1 The Western Australia
screening trial38 reported outcomes by smoking status in the
screened group. The trial was underpowered to detect differences
in subpopulations. No comparisons in the unscreened group were
reported.1,39 None of the 4 population-based screening RCTs re-
ported family history of AAA in the trial populations.1
The prevalence of AAA in male screening participants ranged
from 4.0% to 7.6% across the studies. Most screen-detected AAAs
were small (4 to 4.5 cm in diameter); 0.3% to 0.6% of screened
participants had an AAA measuring 5 cm or larger or 5.5 cm or larger
in diameter.1 Two of the population-based screening trials ana-
lyzed AAA-associated mortality by age. The Viborg trial found simi-
lar risk reduction in AAA-related mortality in screening men aged 64
to 65 years compared with men aged 66 to 73 years.13 The West-
ern Australia trial found no AAA-associated mortality benefit in men
aged 65 to 74 years (rate ratio, 0.92 [95% CI, 0.62-1.36]) at 12.8-
year follow-up; results were similar to findings for men aged 64 to
83 years.1,38
As noted previously, only the Chichester trial included women
(aged 65-80 years). It found a low prevalence of AAA in women
(1.3%), and 75% of screen-detected AAAs in women were 3.0 to
3.9 cm in diameter. Rupture rates (0.2% in both groups), AAA-
specific mortality (0.06% vs 0.04% in both groups), and all-cause
mortality (10.7% vs 10.2%) at 5 years did not statistically signifi-
cantly differ between the invitation-to-screening and control
groups.1,33 The trial was underpowered to draw definitive conclu-
sions about health outcomes in women. Although the risk for rup-
ture at a smaller aneurysm diameter seems to be higher in women
than in men,1,40 the overall rupture rate in women is low. In the
Chichester trial, more than two-thirds of deaths from AAA occurred
in women 80 years or older.1,33
Pooled analysis of AAA-related mortality from the 4 trials
showed a statistically significant 35% reduction associated with
invitation to screening (Peto OR, 0.65 [95% CI, 0.57-0.74];
I2 = 80%).1 The number needed to screen was 305 men (95% CI,
248-411) to prevent 1 AAA death. The MASS and Viborg trials
each found a statistically significant reduction in AAA-related
mortality in the groups invited to screening compared with the
control groups up to 13 years after screening (hazard ratio [HR],
0.58 [95% CI, 0.49-0.69] and 0.34 [95% CI, 0.20-0.57],
respectively).13,36 The Chichester trial reported an HR of less than 1
(HR, 0.89 [95% CI, 0.60-1.32]), but it was not statistically
significant.1,37 Pooled analysis of all available trials also showed no
effect on all-cause mortality (relative risk, 0.99 [95% CI, 0.98-
1.00]; I2 = 0%).1 Of the individual trials, only MASS showed a sta-
tistically significant benefit of screening for all-cause mortality at
up to 15-year follow-up (HR, 0.97 [95% CI, 0.95-0.99]).1 Invitation
to screening was associated with a statistically significant reduced
rate of rupture in the pooled analysis of the 4 trials (Peto OR, 0.62
[95% CI, 0.55-0.70]; I2 = 53%).1 The number needed to screen
was 246 men (95% CI, 207-311) to prevent 1 AAA rupture. Pooled
results of the trials showed a reduction in emergency surgery in
the invited-to-screening group (Peto OR, 0.57 [95% CI, 0.48-
0.68]; I2 = 27%).1 Screening 1000 men for AAA would decrease
the number of emergency operations by 2 (95% CI, 2-2).1
Treatment
Four trials evaluated early surgical intervention compared with
surveillance of smaller aneurysms (4-5.4 cm in diameter).41-44
Two good-quality open repair trials (n = 2226) and 2 fair-quality
EVAR trials (n = 1088) showed no differences in all-cause and
AAA-related mortality. However, there was a reduction in rupture
rate with early open surgery compared with surveillance for small
AAAs12,16,37,38 in the Aneurysm Detection and Management
(ADAM) Veterans Affairs trial (relative risk, 0.18 [95% CI, 0.04-
0.81]) and the UK Small Aneurysm Trial (UKSAT) (relative risk,
0.51 [95% CI, 0.26-0.99]).1,41,42 Individual patient data meta-
analysis of the 2 early open vs surveillance trials (ADAM and
UKSAT) reported no differences in all-cause mortality effect by
sex or age.1,36,37 The UKSAT trial reported no difference in all-
cause mortality by smoking status; there were no analyses strati-
fying by family history or race/ethnicity.1
Seven pharmacotherapy RCTs (n = 1553) of antibiotics, antihy-
pertensive medications (eg, angiotensin-converting enzyme inhibi-
tors, calcium channel blockers, and propranolol), and a mast cell
stabilizer showed no significant effect on AAA growth compared
with placebo.1
Harms of Screening and Treatment
An individual’s risk for death related to elective surgery for AAA is
lower than that related to emergency surgery for aneurysm rup-
ture. However, the increase in the overall rates of detection and sur-
gery in the screening groups still potentially represents a harm. The
extent of overdiagnosis and overtreatment is difficult to estimate.
Each of the 4 older screening trials and a more recent
population-based screening RCT (n = 18 614), the Viborg Vascular
(VIVA) trial, showed an increase in elective operations in the inter-
vention vs control group.1,45 There were approximately 40% more
operations in the invitation-to-screen group than in the control
group (5 studies; n = 175 085; Peto OR, 1.44 [95% CI, 1.34-1.55]),
driven primarily by an increase in elective operations (5 studies;
n = 175 085; Peto OR, 1.75 [95% CI, 1.61-1.90]).1 There was no sta-
tistically significant difference in 30-day mortality rates between
the invited and control groups for either elective or emergency
operations at 12- to 15-year follow-up.1
Five studies (n = 2734) reported mixed results on quality-of-
life outcomes.1 Overall, there were no substantial differences on
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quality-of-life measures or anxiety or depression scores at up to 12
months of follow-up between patients who screened positive for an
AAA and patients who screened negative or were unscreened.1
Two trials of early open repair vs surveillance (ADAM and
UKSAT trials) reported a 50% higher rate of procedures in the
early intervention group, with no difference in 30-day operative
mortality.1,41,42 Readmission rates at 30 days were similar, and
major surgical complications were lower in the early intervention
group. Analysis of quality-of-life measures showed mixed results;
although there was generally a decline in both groups over time,
there were no statistically significant differences between the
groups for up to 1 to 2 years. Only the ADAM trial showed higher
general health scores in the early repair group in the first 2 years,
but this difference did not persist over time.1 One trial reported an
increased incidence of impotence in the early repair group at up
to 4 years’ follow-up.1
Registry harms data were generally comparable to the find-
ings of the 2 trials, with the exception of reintervention rates, which
were higher in the registries than in the ADAM trial.1
Two trials of early EVAR vs surveillance reported approxi-
mately 100% more procedures in the early intervention group and
similarly rare 30-day operative mortality rates between the
groups.1,43,44 In the Comparison of Surveillance vs Aortic Endograft-
ing for Small Aneurysm Repair (CAESAR) trial, the early interven-
tion group had a higher percentage of patients with any adverse
events (19% vs 5%; P < .01), any major morbidity related to repair
at 30 days (18% vs 6%; P = .01), endoleaks at 1 year (12% vs 2%;
P = .028), and reintervention (6% vs 0%; P = .03) but similar rates
of any major morbidity over the trial duration (3.3% vs 2.8%;
P = .99).1,43 The Positive Impact of Endovascular Options for Treat-
ing Aneurysms Early (PIVOTAL) trial reported similar rates of ad-
verse events at 30 days (12% vs 10%) and at 1 year (26% vs 35%),
as well as reintervention (3.7% vs 4.6%).1,44 Reported complica-
tion rates from registry data were generally comparable with rates
reported in the above trials for 30-day operative mortality and
reintervention.1
Two propranolol trials reported high discontinuation rates re-
lated to adverse events (38% and 60% of participants in the pro-
pranolol groups withdrew from the trials). Other medications
(eg, angiotensin-converting enzyme inhibitors, calcium channel
blockers, and antibiotics) seemed well tolerated based on rare trial
withdrawals reported from 1 to 2 studies per drug class.1
Response to Public Comment
A draft version of this recommendation statement was posted for
public comment on the USPSTF website from June 18 to July 15,
2019. Some comments expressed concerns about the harms of
screening. In response, the USPSTF added information about over-
treatment as a harm of screening to the Supporting Evidence sec-
tion and added information about comorbid conditions to the Prac-
tice Considerations section. Some comments urged more research
in diverse populations. The USPSTF clarified its call for research in
the Research Needs and Gaps section. Some comments suggested
expanding the populations for whom screening is recommended.
The USPSTF did not expand the scope of its recommendation be-
yond the populations justified by its review of the current evidence
and recommends research about the benefits and harms of screen-
ing in these groups.
Research Needs and Gaps
Addressing several key research gaps could help inform the benefit
of screening for AAA in US-based populations1:
• Although evidence shows that women who smoke or have a fam-
ily history are at increased risk for AAA compared with nonsmok-
ing women without a family history, evidence is insufficient that
screening this population confers a net benefit. Ideally, appropri-
ately powered RCTs among women with risk factors could an-
swer these critical gaps in the evidence on screening for AAA. In
the absence of new trial data, high-quality, well-calibrated mod-
eling studies based on reliable data on the harms and benefits of
screening in women who smoke or in men and women with a fam-
ily history of AAA may be informative.
• Well-conducted cohort studies examining rescreening benefits
(including growth rates and health outcomes) are needed for per-
sons who initially screen negative for AAA to determine the ben-
efit and timing of additional screening ultrasonography.
• External validation of risk prediction models that have already been
developed will allow policy makers to assess their value for mak-
ing more individualized screening recommendations.
• Epidemiologic studies on the current prevalence of AAA in the
United States, including in subpopulations, would help inform the
applicability of older population-based screening trials to the cur-
rent US population.
• Well-designed studies, RCTs, or registry data on the thresholds for
repair of AAA in women may inform the benefits and harms of
screening in women, as evidence suggests that AAAs in women may
rupture at a smaller size than in men.
• Studies examining systems approaches to improving implemen-
tation of evidence-based AAA screening in the United States
are needed.
• Studies examining the efficacy of screening and treatment in di-
verse populations (eg, older adults, women, and racial/ethnic
groups) are needed to inform the need for specific recommenda-
tions in subpopulations of Americans.
Recommendations of Others
The American College of Cardiology and the American Heart Asso-
ciation jointly recommend 1-time screening for AAA with physical
examination and ultrasonography in men aged 65 to 75 years who
have ever smoked or in men 60 years or older who are the sibling
or offspring of a person with AAA. These organizations do not rec-
ommend screening for AAA in men who have never smoked or in
women.46 The Society for Vascular Surgery recommends 1-time
ultrasonography screening for AAA in all men and women aged 65
to 75 years with a history of tobacco use, men 55 years or older with
a family history of AAA, and women 65 years or older who have
smoked or have a family history of AAA.47 The American College of
Preventive Medicine recommends 1-time screening in men aged 65
to 75 years who have ever smoked; it does not recommend routine
screening in women.48
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